This study includes two parts:~Part 1 - A training period of a single arm active treatment open label, to assess the optimal method of study drug administration, as well as the safety of the combined administration, on 5 patients.~Following DSMB review of the data collected in part 1 and the DSMB approval to proceed to next part, part 2 will be initiated.~Part 2 - A randomized (1:1) placebo controlled 2 arms study. Additional 95 patients will be recruited to this arm.~Patients who are hospitalized due to moderate or severe COVID-19 will be recruited to this study.~The following elements are the main elements that will be assessed:~Confirmation SARS-CoV-2 infection~Respiratory Function (breathing rate, SpO2 Oxygen Saturation~Vital Signs (BP, HR), Temperature~Blood Tests~Disease Severity Scale (8 points ordinal scale)~The whole study period per patient will be 22 days (21 treatment days) or until the patient has recovered and/or is discharged from the hospital, whichever comes first.
This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo and BAT for the treatment of Moderate to Severe COVID-19 patients. The purpose of this study is to assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC).